Business
Stem Cell Therapy
Organoid
Stem Cell and CDMO Business
R&D
Core Technology
| Date | Title | Presentation Obligator |
|---|---|---|
|
23 2026.01 |
30% or More Change in Sales or Profit/Loss(15% or more in the case of large-scale corporations) | |
|
30 2025.12 |
[Investment Caution] Issue traded by linked accounts with high market influence | |
|
11 2025.11 |
Material Management Information related to Judgment of Investment(Approval for IND Modification)(퓨어스템-에이디주(FURESTEM-AD Inj.)의 반복투여 제1/2a 임상시험계획 변경승인) | |
|
01 2025.09 |
Additional Listing(주주배정 후 실권주 일반공모) | KOSDAQ STOCK MKT. |
|
25 2025.08 |
Results of issuance(Voluntary Disclosure) | |
|
19 2025.08 |
Results of Subscription (Voluntary Disclosure) | |
|
12 2025.08 |
Designation of overheated short-selling issues (applied by a restriction on short-selling) | KOSDAQ STOCK MKT. |
|
12 2025.08 |
[Revised]Decision on Paid-in Capital Increase(주주배정후 실권주 일반공모) | |
|
12 2025.08 |
Final Issue Price of Rights Offering | |
|
25 2025.07 |
Subscription Right Newly listed(강스템바이오텍 25R) | KOSDAQ STOCK MKT. |